Distant metastases in ovarian cancer: Association with p53 mutations

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2485-2490

  Sood, Anil K ^a   Sorosky, Joel I ^a   Dolan, Marisa ^a   Anderson, Barrie ^a   Buller, Richard E ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; FRAMESHIFT MUTATION; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MISSENSE MUTATION; NONSENSE MUTATION; OVARY CANCER; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENES, P53; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032853554     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Vaccarello, L., Rubin, S. C., Vlamis, V., Wong, G., Jones, W. B., Lewis, J. L., and Hoskins, W. J. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol. Oncol., 57: 61-65, 1995.
2. Geisler, J. P., and Geisler, H. E. Brain metastases in epithelial ovarian carcinoma. Gynecol. Oncol., 57: 246-249, 1995.
3. Ansell, S. M., Rapoport, B. L., Falkson, G., Raats, J. I., and Moeken, C. M. Survival determinants in patients with advanced ovarian cancer. Gynecol. Oncol., 50: 215-220, 1993.
4. Buller, R. E., Vasilev, S., and DiSaia, P. J. CA125 kinetics: a cost effective clinical tool to evaluate clinical trial outcomes in the 1990s. Am. J. Obstet. Gynecol., 174: 1241-1254, 1996.
5. Kohn, E. C., and Liotta, L. A. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res., 55: 1856-1562, 1995.
6. MacDonald, N. J., and Steeg, P. S. Molecular basis of tumour metastasis. Cancer Surv., 16: 175-199, 1993.
7. Volpert, O. V., Dameron, K. M., and Bouck, N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene, 14: 1495-1502, 1997.
8. Kieser, A., Weich, H. A., Brandner, G., Marme, D., and Kolch, W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene, 9: 963-969, 1994.
9. Tamakoshi, K., Kikkawa, F., Nawa, A., Ishikawa, H., Mizuno, K., Tamakoshi, A., Yamagata, S., Suganuma, N., and Tomoda, Y. Characterization of extracellular matrix-degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form. Cancer (Phila.), 76: 2565-2571, 1995.
10. Mandai, M., Konishi, I., Komatsu, T., Mori, T., Arao, S., Nomura, H., Kanda, Y., Hiai, H., and Fukumoto, M. Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and k-ras mutation in ovarian carcinoma: correlation with tumour progression and nm23 gene expression. Br. J. Cancer, 72: 691-695, 1995.
11. Scambia, G., Panici, P. B., Ferrandina, G., Salerno, G., D'Agostino, G., Distefano, M., diVincenzo, R., Ercoli, A., and Mancuso, S. Clinical significance of cathepsin D in primary ovarian cancer. Eur. J. Cancer, 30A: 935-940, 1994.
12. Darai, E., Scoazec, J. Y., Walker-Combrouze, F., Mlika-Cabanne, N., Feldmann, G., and Madelenat, P. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum. Pathol., 28: 922-928, 1997.
13. Mukhopadhyay, D., Tsiokas, L., and Sukhatme, V. P. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res., 55: 6161-6165, 1995.
14. Dameron, K. M., Volpert, O. V., Tainsky, M. A., and Bouck, N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (Washington DC), 265: 1582-1584, 1994.
15. Buttitta, F., Marchetti, A., Gadducci, A., Pellegrini, S., Morganti, M., Carnicelli, V., Cosio, S., Gagetti, O., Genazzani, A. R., and Bevilacqua, G. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br. J. Cancer, 75: 230-235, 1997.
16. Levesque, M. A., Katsaros, D., Yu, H., Zola, P., Sismondi, P., Giardina, G., and Diamandis, E. P. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer (Phila.), 75: 1327-1338, 1995.
17. Victorzon, M., Nordling, S., Haglund, C., Lundin, J., and Roberts, P. J. Expression of p53 protein as a prognostic factor in patients with gastric cancer. Eur. J. Cancer, 32A: 215-220, 1996.
18. Silvestrini, R., Benini, E., Veneroni, S., Daidone, M. G., Tomasic, G., Squicciarini, P., and Salvadori, B. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J. Clin. Oncol., 14: 1604-1610, 1996.
19. Gasparini, G., Weidner, N., Maluta, S., Pozza, F., Boracchi, P., Mezzetti, M., Testolin, A., and Bevilacqua, P. Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int. J. Cancer, 55: 739-744, 1993.
20. Fontanini, G., Vignati, S., Bigini, D., Mussi, A., Lucchi, M., Angeletti, C. A., Basolo, F., and Bevilacqua, S. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br. J. Cancer, 71: 1003-1007, 1995.
21. Faille, A., De Cremoux, P., Extra, J. M., Linares, G., Espie, M., Bourstyn, E., DeRocquancourt, A., Giacchetti, S., Marty, M., and Calvo, F. p53 mutations and overexpression in locally advanced breast cancers. Br. J. Cancer, 69: 1145-1150, 1994.
22. Goh, H. S., Chan, C. S., Khine, K., and Smith, D. R. p53 and behaviour of colorectal cancer. Lancet, 344: 233-234, 1994.
23. Kupryjanczyk, J., Thor, A. D., Beauchamp, R., Merritt, V., Edgerton, S. M., Bell, D. A., and Yandell, D. W. p53 gene mutations and protein accumulation in human ovarian cancer. Proc. Natl. Acad. Sci. USA, 90: 4961-4965, 1993.
24. Skilling, J. S., Sood, A. K., Niemann, T., Lager, D. J., and Buller, R. E. An abundance of p53 null mutations in ovarian carcinoma. Oncogene, 13: 117-123, 1996.
25. Klemi, P. J., Pylkkanen, L., Kiilholma, P., Kurvinen, K., and Joensuu, H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer (Phila.), 76: 1201-1208, 1995.
26. Marks, J. R., Davidoff, A. M., Kerns, B. J., Humphrey, P. A., Pence, J. C., Dodge, R. K., Clarke-Pearson, D. L., Iglehart, J. D., Bast, R. C., Jr., and Berchuck, A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res., 51: 2979-2984, 1991.
27. Heller, M. J., Burgart, L. J., TenEyck, C. J., Anderson, M. E., Greiner, T. C., and Robinson, R. A. An efficient method for the extraction of DNA from formalin-fixed, paraffin-embedded tissue by sonication. BioTechniques, 1: 372-377, 1991.
28. Skilling, J. S., Powills, K., Lager, D. J., Anderson, B., Sorosky, J., and Buller, R. E. p53 allelotypes and enhanced detection of allelic loss in ovarian cancer: lack of correlation with familial and clinical factors. Gynecol. Oncol., 61: 180-188, 1996.
29. Buller, R. E., Sood, A., Fullenkamp, C., Sorosky, J., Powills, K., and Anderson, B. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther., 4: 239-245, 1997.
30. Marsoni, S., Torri, V., and Valsecchi, M. G. Prognostic factors in advanced epithelial ovarian cancer. Br. J. Cancer, 62: 444-450, 1990.
31. Omura, G. A., Brady, J. F., Homesley, H. D., Yordan, E., Major, F. J., Buchsbaum, H. J., and Park, R. C. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma; the Gynecologic Oncology Group experience. J. Clin. Oncol., 9: 1138-1150, 1991.
32. Seewaldt, V. L., Figge, D. C., Greer, B. E., Tamimi, H. K., Brown, W. S., and Cain, J. M. Primary central nervous system recurrence after paclitaxel therapy for epithelial ovarian malignancy. Gynecol. Oncol., 55: 456-458, 1994.
33. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
34. Kim, K. M., Lee, A., Chae, H. S., and Shim, S. I. Expression of p53 and NDP-K/nm23 in gastric carcinomas: association with metastasis and clinicopathologic parameters. J. Kor. Med. Sci., 6: 406-413, 1995.
35. Ruttledge, M. H., Andermann, A. A., Phelan, C. M., Claudio, J. O., Han, F. Y., Chretien, N., Rangaratnam, S., MacCollin, M., Short, P., Parry, D., Michels, V., Riccardi, V. M., Weksberg, R., Kitamura, K., Bradburn, J. M., Hall, B. D., Propping, P., and Rouleau, G. A. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am. J. Hum. Genet., 59: 331-342, 1996.
36. Tomlinson, F. H., Jenkins, R. B., Scheithauer, B. W., Keelan, P. A., Ritland, S., Parisi, J. E., Cunningham, J., and Olsen, K. D. Aggressive medulloblastoma with high-level N-myc amplification. Mayo Clin. Proc., 69: 359-365, 1994.
37. Sood, A. K., and Buller, R. E. Genomic instability in ovarian cancer: a reassessment using an arbitrarily primed polymerase chain reaction. Oncogene, 13: 2499-2504, 1996.
38. Sood, A. K., Skilling, J. S., and Buller, R. E. Ovarian cancer genomic instability correlates with p53 frameshift mutations. Cancer Res., 57: 1047-1049, 1997.
39. Egawa, S., Uchida, T., Suyama, K., Wang, C., Ohori, M., Irie, S., Iwamura, M., and Koshiba, K. Genomic instability of microsatellite repeats in prostate cancer: relationship to clinicopathological variables. Cancer Res., 55: 2418-2421, 1995.
40. Usmani, B. A., and Sherbet, G. V. Homologous recombination in variants of the B16 murine melanoma with reference to their metastatic potential. J. Cell. Biochem., 61: 1-8, 1996.
41. Hurford, R. K., Dranoff, G., Mulligan, R. C., and Tepper, R. I. Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nat. Genet., 10: 430-435, 1995.
42. Lesoon-Wood, L. A., Kim, W. H., Kleinman, H. K., Weintraub, B. D., and Mixson, A. J. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum. Gene Ther., 6: 395-405, 1995.